{"id":"low-dose-rtpa","safety":{"commonSideEffects":[{"rate":null,"effect":"Intracranial hemorrhage"},{"rate":null,"effect":"Systemic bleeding"},{"rate":null,"effect":"Reperfusion injury"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"rtPA (recombinant tissue plasminogen activator) is a serine protease that binds to fibrin in blood clots and catalyzes the conversion of plasminogen to plasmin, which degrades fibrin and dissolves the clot. At lower doses than standard thrombolytic regimens, it aims to achieve thrombolysis while potentially reducing bleeding complications. The George Institute is investigating low-dose rtPA formulations for acute stroke and other thromboembolic conditions.","oneSentence":"Low-dose rtPA is a thrombolytic agent that activates plasminogen to dissolve blood clots by converting it to plasmin.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:37.149Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Acute pulmonary embolism"}]},"trialDetails":[{"nctId":"NCT04088292","phase":"PHASE3","title":"Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2019-06-06","conditions":"Pulmonary Embolism","enrollment":210},{"nctId":"NCT05172115","phase":"PHASE3","title":"Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE","status":"TERMINATED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2018-12-22","conditions":"Pulmonary Embolism, Pulmonary Thromboembolisms, Embolism, Pulmonary","enrollment":94},{"nctId":"NCT01422616","phase":"PHASE3","title":"Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)","status":"COMPLETED","sponsor":"The George Institute","startDate":"2012-03","conditions":"Ischemic Stroke, High Blood Pressure","enrollment":4587},{"nctId":"NCT03108833","phase":"PHASE2","title":"A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2017-06-06","conditions":"Acute Pulmonary Embolism","enrollment":108},{"nctId":"NCT04676659","phase":"PHASE2","title":"Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events(TRACE)","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2018-05-12","conditions":"Acute Ischemic Stroke","enrollment":240},{"nctId":"NCT02787278","phase":"PHASE2","title":"Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2016-06-05","conditions":"Ischemic Stroke","enrollment":80},{"nctId":"NCT04110275","phase":"PHASE2","title":"Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)","status":"UNKNOWN","sponsor":"Angde Biotech Pharmaceutical Co., Ltd.","startDate":"2019-10","conditions":"Acute Pulmonary Embolism","enrollment":174},{"nctId":"NCT03847883","phase":"PHASE4","title":"Low-dose Versus Standard Dose Alteplase in Acute Ischemic Stroke , 4 Monthes Prospective Study","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2011-01-01","conditions":"Acute Stroke","enrollment":408},{"nctId":"NCT00055159","phase":"PHASE1","title":"Low-Dose rtPA to Treat Blood Clots in Major Arm or Neck Veins","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2003-02-19","conditions":"Thrombosis","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Actilyse"],"phase":"phase_3","status":"active","brandName":"Low-dose rtPA","genericName":"Low-dose rtPA","companyName":"The George Institute","companyId":"the-george-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose rtPA is a thrombolytic agent that activates plasminogen to dissolve blood clots by converting it to plasmin. Used for Acute ischemic stroke, Acute pulmonary embolism.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}